Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dimethyl sulfoxide is a small-molecule polar aprotic solvent with tissue-penetrating, anti-inflammatory, analgesic, and vasodilatory pharmacologic effects that are not attributable to a single defined molecular target. In the United States, a sterile 50% aqueous dimethyl sulfoxide product is marketed as RIMSO-50 for intravesical symptomatic relief of interstitial cystitis. Dimethyl sulfoxide is also used topically as a pharmaceutical vehicle and penetration enhancer; Mahidol University evaluated 30% topical dimethyl sulfoxide alone versus topical amphotericin B in 30% dimethyl sulfoxide in a randomized pilot study of non-dermatophyte onychomycosis. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=58b25d79-78f2-4953-b0c6-61658dc4ef0d))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dimethyl sulfoxide (Mahidol University).